NDRA
ENDRA Life Sciences Inc.·Healthcare
4.94
6.968%(−0.37)
Market ClosedLast Updated: — ET
52W L: $2.9052W H: $11.96
NDRA NEWS
businesswire.com
Mar 31
ENDRA Life Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
ANN ARBOR, Mich.--(BUSINESS WIRE)---- $NDRA #MASLD--ENDRA Life Sciences Inc. (NASDAQ: NDRA) (“ENDRA” or the “Company”), a pioneer in thermoacoustic biomarker imaging for early detection and monitoring of steatotic liver disease (SLD), today reported financial results for the quarter and year ended December 31, 2025, and provided a business update. Business Update Initiated Evaluation of Strategic Alternatives On March 25, 2026, the Company announced that its Board of Directors has initiated a process to evaluat.
businesswire.com
Mar 25
ENDRA Life Sciences Initiates Review of Strategic Alternatives to Maximize Shareholder Value
ANN ARBOR, Mich.--(BUSINESS WIRE)---- $NDRA #MASLD--ENDRA Life Sciences Inc. (Nasdaq: NDRA) (“ENDRA” or the “Company”), a pioneer in thermoacoustic biomarker imaging for early detection and monitoring of steatotic liver disease (SLD), today announced that its Board of Directors has initiated a process to evaluate a range of strategic alternatives aimed at maximizing shareholder value. As a part of this process, the Board will evaluate a range of potential alternatives, including, but not limited to strategic in.
defenseworld.net
Mar 23
ENDRA Life Sciences (NDRA) Expected to Announce Quarterly Earnings on Monday
ENDRA Life Sciences (NASDAQ: NDRA - Get Free Report) is expected to be issuing its Q4 2025 results before the market opens on Monday, March 30th. Analysts expect the company to announce earnings of ($1.23) per share for the quarter. Individuals may visit the the company's upcoming Q4 2025 earning results page for the latest details
zacks.com
Mar 3
NDRA's TAEUS Device Achieves MRI-Level Liver Imaging Precision
ENDRA posts strong TAEUS Liver study data, showing high measurement reliability for MASLD monitoring and boosting its regulatory and commercial outlook.
businesswire.com
Feb 26
ENDRA's TAEUS® Liver Device Demonstrates High-Level Consistency in Clinical Study, Delivering MRI-Level Results at the Point of Patient Care
ANN ARBOR, Mich.--(BUSINESS WIRE)---- $NDRA #MASLD--ENDRA Life Sciences Inc. (NASDAQ: NDRA) (“ENDRA” or the “Company”), a pioneer in thermoacoustic biomarker imaging for the early detection and monitoring of steatotic liver disease (SLD), today announced favorable results from a clinical study evaluating the measurement consistency of its TAEUS® Liver device. The study demonstrated the device's robust intra-user repeatability and inter-user reproducibility, essential factors for long-term monitoring of Metaboli.
